natgillin/translations-raw huggingface dataset:
a heavy chain comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:48, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:72, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:96, and a light chain comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:12, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:24, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:36; or 
teški lanac koji obuhvaća HVR-H1 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 48, HVR-H2 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 72, i HVR-H3 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 96, te laki lanac koji obuhvaća HVR-L1 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 12, HVR-L2 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 24, i HVR-L3 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 36; ili
A method of treating a disease comprising administering to a subject in need thereof an effective amount of a composition comprising an antibody selected from claims 1-26, wherein said disease is asthma, arthritis, autoimmune heart disease, multiple sclerosis, inflammatory bowel disease, ischemia-reperfusion injuries, Barraquer-Simons Syndrome, hemodialysis, systemic lupus, lupus erythematosus, psoriasis, multiple sclerosis, transplantation, Alzheimer's disease, glomerulonephritis, or MPGN II. 
Protutijelo ili njegov fragment koji se veže na antigen prema bilo kojem od zahtjeva 1 do 8, ili farmaceutski sastav prema zahtjevu 9, naznačen/o time, da se upotrebljava u liječenju sljedećih stanja: makularna degeneracija povezana sa starošću, astma, artritis, autoimuna srčana bolest, multipla skleroza, upalna bolest crijeva, ishemijske-reperfuzijske ozljede, sindrom Barraquer-Simons, sistemski lupus, lupus eritematoza, psorijaza, multipla skleroza, Alzheimerova bolest, < glomerulonefritis, -paroksizmalna -nokturalna hemoglobinurija (PNH) ili MPGN II.
is hydrogen, CH3, CH2CH3, or R1 and the carbon to which it is bound form a C=CH2 group; 
R' je vodik, CH, ili CH>CH,, ili R' i ugljik na kojeg je vezan tvore skupinu C=CH>;
The beverage of claim 2, wherein Reb X is present in a concentration from 50 to 600 ppm and Reb A is present in a concentration from 10 to 500 ppm. 
Napitak prema zahtjevu 2, naznačen time da Reb X je prisutan u koncentraciji od 50 do 600 ppm i Reb A je prisutan u koncentraciji od 10 do 500 ppm.
The compound of claim 1, for use in the treatment of diabetes, wherein the compound is administered to the same patient every 2nd day or less frequently, and, on average, during a period of time of at least 1 month, 6 months or 1 year, said compound is not administered more frequently to the same patient. 
Spoj prema patentnom zahtjevu 1, za uporabu u tretmanu dijabetesa, naznačeno time da je spoj primijenjen na istog pacijenta svaki drugi dan, ili rjeđe, 1, u prosjeku, tijekom vremenskog perioda od najmanje 1 mjeseca, 6 mjeseci ili 1 godine, navedeni spoj nije primjenjen češće na istog pacijenta.
The stable growth conditions enable to subculture cells easily by repeated dilution with a ratio 1:4 over extended period of time (tested up to day 62, as shown in Figs. 
Stabilni uvjeti rasta omogućuju laku subkultivaciju stanica ponavljanim razrjeđenjem u omjeru 1:4 tijekom dužeg vremenskog razdoblja (provjereno do dana 62., kako je prikazano na si.
A composition comprising a compound of any one of claims 1 to 19, or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 
Sastav, naznačen time da sadrži spoj bilo kojeg zahtjeva od 1 do 51 ili njegovu farmaceutski prihvatljivu sol i najmanje jedan farmaceutski prihvatljivi nosač.
about 5% sucrose; about 0.2% polysorbate 20; and 
polisorbat 20 u koncentraciji od oko 0,2 %; i
There is also a need for pharmaceutical compositions containing such GnRH receptor antagonists, as well as methods relating to the use thereof to treat, for example, sex-hormone related conditions. 
Također postoji potreba za farmaceutskim pripravcima koji sadržavaju takve antagoniste receptora GnRH, kao i postupcima koji se odnose na njihovu upotrebu u liječenju, primjerice, stanja povezanih sa spolnim hormonima.
wherein the heterologous amino acid sequence encodes an immunogen, a T-cell epitope, a B-cell epitope, a fragment of any of said heterologous peptides, and a combination of two or more of said heterologous peptides. 
pri čemu heterologna sekvenca aminokiseline kodira imunogen, epitop T-stanica, epitop B-stanica, odsječak bilo kojeg od navedenih heterolognih peptida, i kombinaciju dva ili više navedenih heterolognih peptida.
Dispensing device (1) according to claim 9, wherein said processing and driving unit is configured to set said pre-established quantity of coffee-beans and for timing its conveyance from the contaiment tank (2) to the grinding means (7). 
Uređaj za točenje (1) prema patentnom zahtjevu 7, gdje je navedena jedinica za preradu i pokretanje konfigurirana da odredi unaprijed ustanovljenu količinu zrna kave i da mjeri vrijeme njihovog prijenosa od rezervoara za držanje (2) do sredstava za mljevenje (7).
The extended release tablet formulation of claim 1, wherein the matrix comprises pregelatinized starch, hydroxypropylmethylcellulose, acrylic acid polymerisate and excipients, and the resulting tablet provides a ph-dependent release characteristic with a faster release characteristic in the range of pH < 4.5, and a slower and further on pH-independent release characteristic in the range from pH 4.5 to 7.5. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 1, naznačena time, da rezultirajuća tableta osigurava pH-ovisno oslobađanje karakterizirano bržim oslobađanjem karakterističnim u rasponu pH < 4.5, te sporijim i nadalje pH-neovisnim oslobađanjem karakterističnim u rasponu od pH 4.5 do 7.5.
The humanized monoclonal anti-IL-23p19 antibody according to claim 11, wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:174 and a heavy chain comprising the amino acid sequence of SEQ ID NO:178. 
Humanizirano anti-IL-23p19 protutijelo u skladu s patentnim zahtjevom 11, pri čemu navedeno protutijelo sadrži laki lanac koji sadrži aminokiselinski slijed SEQ ID NO: 174 i teški lanac koji sadrži aminokiselinski slijed SEQ ID NO: 178.
The compound of claim 1 which is a compound of formula: or or a pharmaceutically acceptable salt or prodrug thereof. 
HR P20181384 T1 22. Spoj iz patentnog zahtjeva 1 koji je spoj formule: aa
The use of a compound according to claims 15 or 16, in the synthesis of a compound comprising an Y-amino-δ-biphenyl-a-methylalkanoic acid, or acid ester, backbone. 
Uporaba spoja prema zahtjevima 15 ili 16, naznačena time, da je za sintezu spoja koji u kralježnici sadrži Y-amino-δ-bifenil-a-metilalkanoinsku kiselinu, ili ester Y-amino-δ-bifenil-a-metilalkanoinske kiseline.
Furthermore, in areas in which easily flammable materials are worked with, there is the danger that these materials will be ignited by spark-over in the event of static discharges. 
Osim toga, u područjima u kojima se radi s lako zapaljivim materijalima, postoji opasnost da će se ti materijali upaliti iskrom u slučaju statičkih izboja.
A GSK3B inhibitor selected from the group of a dihydrospiro-[cycloalkylamine]-pyrimidone derivative represented by formula (I) or salts thereof, or a solvate thereof or a hydrate thereof according to claim 1. 
Inhibitor GSK3B, naznačen time što ga se bira iz skupine koju čine dihidrospiro[cikloalkilamin]pirimidonski derivati, prikazani formulom (1), ili njihove soli, ili njihovi solvati ili hidrati, prema patentnom zahtjevu 1.
A method of preparing oligomers of an olefin, including providing a composition that includes an alkylaluminum compound, a chromium compound, and a solvent selected from the group consisting of C8-C11 alkane compounds having one branch, n-undecane, and combinations thereof and contacting an olefin with the composition to provide a solution that includes oligomers of the olefin. 
Postupak priprave oligomera olefina, naznačen time što se sastoji u: osiguravanju smjese koja sadrži alkilaluminijev spoj, spoj kroma, te otapalo kojeg se bira iz skupine koju čine C8-C11 alkanski spojevi s jednom granom, n-undekan, te njihove kombinacije; i stavljanju u kontakt olefina sa smjesom kako bi se dobilo otopinu koja sadrži oligomere olefina.
The antigen binding protein or the composition claim 10, wherein the fibrotic disorder is selected from the group consisting of scleroderma, interstitial lung disease, idiopathic pulmonary fibrosis, fibrosis arising from chronic hepatitis B or C, radiation-induced fibrosis, and fibrosis arising from wound healing. 
13. Sastav za uporabu u skladu s patentnim zahtjevom 11, pri čemu je fibrotično stanje odabrano 1z grupe koja se sastoji od skleroderme, intersticijske bolesti pluća, idopatske plućne fibroze, fibroze koja nastaje iz kroničnog hepatitisa B ili C, zračenjem inducirane fibroze i fibroze koja nastaje zacjeljivanjem rana.
an additional active ingredient selected from the group consisting of aspirin, acetaminophen, opioids, ibuprofen, naproxen, COX-2 inhibitors, gabapentin, pregabalin, and tramadol. 
dodatni aktivni sastojak izabran iz grupe koja se sastoji od aspirina, acetaminofena, opioidia, ibuprofena, naproksena, COX-2 inhibitora, gabapentina, pregabalina, i tramadola.
Spraying speed of the pelletizing liquid was set at 50 ml/min, pressure of the spraying air was 2.5 bar. 
Brzina raspršivanja tekućine za granuliranje bila je postavljena na 50 ml/min, a tlak zraka za raspršivanje bio je 2,5 bar.
The HPLC paste was then resolubilised by adding a solution of 0.05 M Na2HPO4 + 1% SDS. 
HPLC pasta se zatim ponovno otopila dodatkom otopine od 0,05 M NaHPO, + 1% SDS.
The present invention therefore relates to oral pharmaceutical compositions containing an active ingredient having antimicrobial/anti-infectious activity, such as rifamycin SV and/or metronidazole, characterized in that they are formulated in such a manner as to release the active substances substantially in the portion of the large intestine where their specific sterilizing action is required, but leaving unaltered the non-pathogenic bacterial flora present in the portions of the small intestine which are not affected by the infection. 
<0,4 Ovaj izum se stoga odnosi na oralne farmaceutske pripravke koji sadrže aktivni sastojak antimikrobne/ antiinfektivno aktivnosti, kao što je rifamicin SV, karakterizirane time da su formulirani na način da se aktivni sastojak značajno otpušta u dijelu debelog crijeva gdje je potrebna specifična aktivnost sterilizacije, a da se pri tome nepatogena bakterijska flora prisutna u dijelovima tankog crijeva koje nije zahvaćeno infekcijom ostavi nepromijenjena.
The method of claim 7, wherein the mouse further comprises a mouse k 3′ enhancer downstream of the endogenous mouse k constant region. 
Metoda prema patentnom zahtjevu 1, koja dodatno sadrži mišji k intronski pojačivač 5' u odnosu na mišju konstantnu regiju lakog lanca.
The dosage form of claim 9 or claim 10, wherein the dosage form is suitable for oral administration. 
Pripravak prema patentnom zahtjevu 7 koji je pogodan za oralnu ili topičku primjenu.
benzyl substituted with 1 or 2 substituents independently selected from the group consisting of chloro, fluoro, and trifluoromethyl. 
benzil, supstituiran s 1 ili 2 supstituenta, koje se neovisno bira iz skupine koju čine klor, fluor, te trifluormetil.
at least one dispersing agent is added to the aqueous suspension of step b), wherein the at least one dispersing agent is added completely before grinding step c), or stepwise before and during grinding step c), or before and during and/or after grinding step c), wherein the at least one dispersing agent is independently selected from the group comprising homopolymers or copolymers of polycarboxylic acids such as acrylic, methacrylic acids or maleic acid; and/or their salts, e.g. 
u vodenu suspenziju iz koraka b) se dodaje barem jedno sredstvo za raspršivanje, pri čemu se barem jedno sredstvo za raspršivanje dodaje u potpunosti prije koraka mljevenja c), ili u obrocima prije i tijekom koraka mljevenja c), ili prije i tijekom i/ili nakon koraka mljevenja c), gdje je barem jedno sredstvo za raspršivanje nezavisno izabrano iz skupine koja sadrži homopolimere ili kopolimere polikarboksilnih kiselina poput akrilne, metakrilne kiseline ili maleinske kiseline; i/ili njihove soli, npr.
Optionally, the coating composition may also include any or all of from about 0.05% to about 1 % antimicrobrials, preferably methylparaben, a small amount of plasticizer, e.g., polysorbate from 0.01 % to 10% by weight of polyvinylidene chloride copolymer; and, preferably 0.005% of an antifoaming agent, such as polydimethylsiloxane. 
Izborno, oblagajuća kompozicija također može sadržavati bilo koji ili sve od: od oko 0.05% do oko 1% antimikrobnih sredstava, poželjno metilparaben, malu količinu plastifikatora, npr. polisorbat od 0.01% do 10% po masi poliviniliden klorid kopolimera; i, poželjno 0.005% sredstva protiv stvaranja pjene, kao što je polidimetil-siloksan.
Caramelisation is commonly defined as the thermal degradation of sugars leading to the formation of volatiles (caramel aroma) and brown-coloured products (caramel colours). 
Karamelizacija se obično definira kao termalna degradacija šećera koja dovodi do stvaranja hlapljivih tvari (aroma karamele) i smeđe obojenih produkata (boje karamele).
As shown in FIG. 1, the molecules of PET are free and the material is transparent and clear. 
Očito je iz Slike 1 da su molekule PET-a slobodne, te da je materijal transparentan i bistar.
The transdermal therapeutic system according to claim 19, which contains a dose of Gestodene of 1.9 mg, a dose of Ethinylestradiol of 0.9 mg, and 97.2 mg polyisobutylene in combination with a tackifier. 
Transdermalni terapeutski sustav u skladu sa zahtjevom 19, naznačen time, da sadrži dozu Gestodena od 1.9 mg, dozu Ftinilestradiola od 0.9 mg i 97.2 mg poliizobutilena u kombinaciji sa tvari za lijepljenje.
The outputs of the receiver are connected to the existing electronic controls of the boat. 
Izlazi prijemnika su spojeni na postojeće elektronske kontrole plovila.
The mooring buoy of claim 8, wherein the RF communication device is further configured to transmit the received vessel ID to a central RF communication device of a mooring buoy booking control system. 
Plutača za privez (101) prema zahtjevu 8, naznačena time što je RF komunikacijski uređaj (403) nadalje prilagođen da prenosi primljeni ID plovila na središnji RF komunikacijski uređaj sustava kontrole rezervacije plutače za privez.
The results obtained are compared to those from 5-isosorbide mononitrate, which is used as reference product. 
Dobiveni rezultati su uspoređeni s onima koji su dobiveni s 5-izosorbid mononitratom, koji je upotrijebljen kao usporedbeni proizvod.
The biomaterial as claimed in claim 1 or 2, containing lidocaine. 
Biomaterijali kako su prijavljeni u prethodnim patentnim zahtjevima, naznačeni time da sadrže lidokain.
In a class of this embodiment, about 5% to about 100% by weight of the crystalline monohydrate is present in the drug substance. 
U jednoj klasi ove implementacije, oko 5% do oko 100% težinski kristalnog monohidrata je nazočno u supstanci lijeka.
the multispecific antigen-binding molecule of [3], wherein the first and second polypeptides further comprise an antibody H chain constant region, and the third and fourth polypeptides comprise an antibody L chain constant region; 
(a) prvi i drugi polipeptid nadalje obuhvaćaju konstantno područje H-lanca protutijela, a treći i četvrti polipeptid obuhvaćaju konstantno područje L-lanca protutijela; ili (b)
The method for recovering heat according to claim 1, in which the low pressure steam obtained from stage 1, or the medium pressure steam obtained from stage 2, is used as heat transporting fluid in order to supply heat to combustion air of furnaces in air pre-heaters. 
Postupak povrata topline u skladu sa zahtjevom 1 naznačen time da se niskotlačna para (LP) iz koraka 1 ili para srednjeg tlaka (MP) iz koraka 2 koristi kao fluid za prijenos topline za dovođenje topline zraku za sagorijevanje za ložišta u predgrijačima zraka.
a charge transporting material, which is an electron transporting material; optionally wherein the porous layer of a p-type semiconductor comprises an oxide of nickel, vanadium, copper or molybdenum; optionally wherein the porous layer of a p-type semiconductor is in contact with a compact layer of a p-type semiconductor, and preferably the compact layer of a p-type semiconductor comprises an oxide of nickel, vanadium, copper, molybdenum or tungsten; and 
(c) materijal za prijenos naboja, koji je materijal za prijenos elektrona; pri čemu porozni sloj poluvodiča p-tipa po izboru sadržava oksid nikla, vanadija, bakra ili molibdena; po izboru porozni sloj poluvodiča p-tipa u kontaktu je s kompaktnim slojem poluvodiča p-tipa, i poželjno kompaktni sloj poluvodiča p-tipa sadržava oksid nikla, vanadija, bakra, molibdena i volframa i po izboru materijal za prijenos elektrona sadržava fuleren ili perilen, njihove derivate ili P.NDI2OD-T2).
Figure 1 shows an X-ray diffraction pattern of tablets comprising donepezil hydrochloride hydrate (upper curve) as well as of pure donepezil hydrochloride hydrate (lower curve). 
Slika 1 prikazuje spektar difrakcije X-zraka na tabletama koje sadrže donepezil hidroklorid hidrat (gornja krivulja) kao 1 čistog donepezil hidroklorid hidrata (donja krivulja).
The compound of claim 1, wherein Z is r is 3 and s is 5. 
r je 3, a s je 5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj [image];
A monoclonal antibody or antigen binding fragment thereof, that binds to human IL-23 at an epitope comprising residues 20-30 and 82-110 of SEQ ID NO: 47, wherein the antibody or antigen binding fragment thereof comprises: a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein: 
HR P20120611 T1 PATENTNI ZAHTJEVI Antitijelo ili antigen-vežući fragment istog koji se veže za humani IL-23, naznačeno time, što sadrži: a) varijabilnu domenu lakog lanca, ili antigen-vežući fragment istog, koja sadrži CDRLI, CDRL2 i CDRL3, pri čemu:
A compound as claimed in claim 1 selected from the following: 
Spoj prema zahtjevu 1 naznačen time da je odabran iz skupine koju čine:
4 illustrates a second embodiment of a shoe according to the invention, generally designated by the reference numeral 200 . 
Slika 4 prikazuje drugo utjelovljenje cipele sukladno predmetnom izumu, općenito označeno brojčanom referencom 200.
the asterisk indicates the point of attachment to (Y)y; and the wavy line indicates the point of attachment to L2. 
O u kojima zvjezdica pokazuje mjesto vezanja za (Y),; te valovita linija pokazuje mjesto vezanja za L.
The cellulose reactive glyoxalated copolymer composition according to claim 1, wherein the cationic copolymer comprises about 20 to about 60 weight % diallyldimethylammonium halide monomer and about 80 to about 40 weight % acrylamide monomer. 
Sastav glioksaliranog kopolimera reaktivnog sa celulozom prema bilo kojem od zahtjeva 1-3, gdje kationski kopolimer sadrži 20 do 60 masena % dialildimetilamonij halid monomera i 80 do 40 masena % akrilamid monomera.
A method for fixing profiles (2) according to claim 10 characterized in that the attachment of the fastening element (4) to the profile (2) can also be made by screwing it into the profile (2). 
Postupak za učvršćivanje profila (2) prema zahtjevu 9 naznačen time da je pričvršćivanje elementa za učvršćivanje (4) na profile (2) izvedeno njegovim učvršćivanjem vijcima na profile (2).
A method of making a pharmaceutical dosage form comprising: combining a therapeutically effective amount of the anamorelin monohydrochloride of claims 1,2 or 3 with one or more pharmaceutically acceptable excipients to form a mixture; and 
4. - Farmaceutski sastav koji sadrži: a) terapeutski efikasnu količinu anamorelin monohidroklorida prema patentnim zahtjevima 1, 2 ili 3; 1 b) jedan ili više farmaceutski prihvatljivih ekscipijenata.
an agent of the invention in inhalable form, e.g., in an aerosol or other atomizable composition or in inhalable particulate, e.g., micronised form; 
(a) sredstvo izuma u obliku koji se može inhalirati, npr. u obliku aerosola ili u drugom obliku sastava koji se može atomizirati ili u obliku čestica koje se mogu inhalirati, npr. u mikroniziranom obliku;
Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof 
Izumom je riješen tehnički problem sinteze novih cis-4-fenil-1,2,3,4-tetrahidro-1-naftalinamina.
Panel as claimed in claim 3 characterized in that said transparent to light material is a plastic material selected from polymethylmethacrylate, epoxy resins, polycarbonates. 
Ploča prema zahtjevu 3, naznačena time što je spomenuti materijal proziran za svijetlost plastični materijal koji je izabran između polimetilmetakrilata, epoksi smola, polikarbonata.
A cement admixture as recited in claim 2, which has a fineness of 2,000 to 7,000 cm2/g as represented in terms of a Blaine's specific surface area value. 
Cementna primjesa u skladu s patentnim zahtjevom 3, naznačena time što kalcijev feroaluminat ima finoću od 2000 do 7000 cm"/g u terminima vrijednosti Blaineove specifične površine.
Receptacle with a lid according to one of claims 10 or 11, characterized in that the first plastic material is General Purpose Polystyrene (GPPS). Receptacle with a lid according to one of claims 10 to 12, characterized in that the second plastic material is High Impact Polystyrene (HIPS). 
Poklopac prema jednom od prethodnih patentnih zahtjeva, naznačen time da su oba navedena, prvi kao i drugi, plastična materijala polistireni, i time daje prvi plastični materijal polistirEn opće namjene (GPPS) i time da je drugi materijal polistiren visokog djelovanja (HIPS).
The compound for the use of claim 1 wherein R10 is hydrogen, X and Y are taken together with the attached carbon to form C(O), V is C(O), W is H or F, A is CH2, B is (CH2)n, n is 3, and C is 3-aminophenyl. 
Spoj za uporabu prema zahtjevu 1 gdje R'" je vodik, X i Y se uzimaju zajedno sa spojenim ugljikom da formiraju C(O), V je C(O), W je F, A je CH2, B je (CH2),, nje 3, 1 € je 3-aminofenil.
Compound 13 was obtained as a white solid from 1,4-diaminobenzene and compound 2 by method C. 
Spoj 13 se dobiva kao bijela krutina iz 1,4-diaminobenzena i spoja 2 pomoću postupka C.
The compound according to Claim 4 or a salt thereof, wherein R1 is phenyl in which the carbon at the 4-position is substituted with a group selected from the group consisting of 4-(4-methylpiperazin-1-yl)piperidin-1-yl, 4-(1-methylpiperidin-4-yl)piperazin-1-yl, 4-methylpiperazin-1-yl, and 4-isopropylpiperazin-1-yl, and the carbon at the 3-position may be substituted with a group selected from the group consisting of fluoro, methyl, trifluoromethyl, and methoxy. 
: -H. Spoj prema zahtjevu 1 ili njegova sol, gdje R1 je fenil u kojem je ugljik na položaju 4 supstituiran skupinom izabranom iz grupe koju čine halogen 4-(4-metilpiperazin-1-il)piperidin-1-il, 4-(1-metilpiperidin-4-il)piperazin-1-il, 4-metilpiperazin-1-il, i 4-izopropilpiperazin-1-il, i ugljik na položaju 3 može biti supstituiran skupinom izabranom iz grupe koju čine fluor, metil, trifluorometil, i metoksi.
Such a compound may be mentioned a compound wherein R1 is a hydrogen atom, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group or hexyl group, 
Medicinska oftalmološka otopina za uporabu prema Zahtjevu 1, gdje R' predstavlja atom vodika, metil skupinu, etil skupinu, propil skupinu, izopropil skupinu, butil skupinu, izobutil skupinu, sec-butil skupinu, tert-butil skupinu, pentil skupinu ili heksil skupinu,
The compound for use according to claim 1, wherein the compound is administered to an affected eye in a dosage of 
Tvar za uporabu u skladu s patentnim zahtjevom 1, pri čemu se tvar primjenjuje u zahvaćeno oko u doziranju